<DOC>
	<DOCNO>NCT01917539</DOCNO>
	<brief_summary>Our primary aim determine whether pulsed light therapy ( PLT ) effective reduce symptom improve clinical stigma dry eye syndrome ( DES ) associate meibomian gland dysfunction ( MGD ) patient facial rosacea ( include ocular rosacea ) . The uses PLT treatment rosacea , hair removal , pigmented lesion , skin telangiectasias . The risk include potential transient sunburn-like sensation ( i.e . redness , burn sensation ) particularly use properly , potential cause burn , blistering , scar , pigmentary change .</brief_summary>
	<brief_title>Efficacy Pulsed Light Therapy Meibomian Gland Dysfunction Dry Eye Syndrome</brief_title>
	<detailed_description>Group 1 : pre-existing dry eye treatment regimen + sham light treatment . Sham light treatment consist apply usual eye shield use PLT , apply usual skin gel facial region , apply cool probe without application pulse light therapy treatment . Group 2 : pre-existing dry eye treatment regimen + pulse light therapy ( PLT ) Subjects recruited outpatient clinic Bascom Palmer Eye Institute , chief complaint dry eye , meet inclusion/exclusion criterion . Subjects randomize via computerassisted random number generation Group 1 2 . All subject undergo baseline evaluation DES include standardized questionnaire symptom dry eye ( take 5 minute complete ass presence severity dry eye symptom ) , various test property composition tear film , grade change relate dry eye see surface eye , grade oil gland eyelid ( meibomian gland ) secretion . Primary outcomes anatomical improvement meibomian gland secretion . Subjects Group 1 continue pre-existing dry eye treatment regimen receive sham light treatment , whereas subject Group 2 continue pre-existing dry eye treatment regimen receive PLT . All subject come initial visit evaluation treatment # 1 take place . They also attend 3 follow-up visit space approximately 3-4 week apart subsequent treatment and/or evaluation dry eye . The visit duration range approximately 60-90 minute per clinic visit . The PLT device FDA approve treatment rosacea periocular/facial region , facial rosacea one inclusion criterion study . This indication treatment PLT . The device FDA-approved treatment DES , although something look one main outcome .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<criteria>Age great equal 18 y/o Patients present academic referral center DES Diagnosis mild moderate DES meibomian gland dysfunction ocular rosacea , base evaluation meibomian gland ( MG ) , MG secretion , factor Facial rosacea Patients must start new medication within past 1 month Patients use warm compress lid scrubs 12 time previous 2 week Symptomatic change DES Age &lt; 18 History inflammatory DES ( e.g . Sjogren 's , rheumatoid arthritis , StevensJohnson syndrome , ocular cicatricial pemphigoid ) History traumainduced ocular surface disease ( thermal burn , chemical burn ) Severe DES Pregnant woman H/o seizures Significant unprotected sun exposure use tan bed cream treat area ( must discontinue least 2 week prior treatment , treatment course , 2 week last treatment ) Use Accutane , anticoagulant , St. John 's Wort Active infections/immunosuppression Herpes 1 2 within treatment area Patients undergone LASIK surgery within past 12 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>